Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.51 |
| ▸ | NOS2 | P35228 | 2/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 4/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.42 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17375664 | 1.00 | PRCP (0.51) | PRCPNOS2NOS3NOS1DPP7 | |
| SCHEMBL5794043 | 1.00 | PRCP (0.51) | PRCPNOS2NOS3NOS1DPP7 | |
| Hydrochloric Acid SCHEMBL28132269 | 0.98 | PRCP (0.50) | PRCPNOS2NOS3NOS1DPP7 | |
| SCHEMBL3862861 | 0.87 | PRCP (0.50) | PRCPNOS2NOS3NOS1DPP7 | |
| SCHEMBL809691 | 0.87 | PRCP (0.50) | PRCPNOS2NOS3NOS1DPP7 | |
| SCHEMBL8591230 | 0.87 | NOS2 (0.50) | PRCPNOS2NOS3NOS1DPP7 | |
| SCHEMBL3862863 | 0.87 | PRCP (0.50) | PRCPNOS2NOS3NOS1DPP7 | |
| SCHEMBL8591235 | 0.87 | NOS2 (0.50) | PRCPNOS2NOS3NOS1DPP7 | |
| SCHEMBL4615012 | 0.84 | PRCP (0.47) | PRCPNOS2NOS3NOS1DPP7 | |
| SCHEMBL5970059 | 0.84 | PRCP (0.44) | PRCPNOS2NOS3NOS1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160971-B1 | METHOD FOR SELECTIVE DETECTION AND ESTIMATION OF HISTIDINE AND CYSTEIN | COUNCIL SCIENT IND RES (IN) | 2019-05-15 | — | — | EP | disclosed |
| US-10155776-B2 | Method for selective detection and estimation of histidine and cystein | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-12-18 | — | — | US | disclosed |
| US-20170240568-A1 | METHOD FOR SELECTIVE DETECTION AND ESTIMATION OF HISTIDINE AND CYSTEIN | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-08-24 | — | — | US | disclosed |
| EP-3160971-A1 | METHOD FOR SELECTIVE DETECTION AND ESTIMATION OF HISTIDINE AND CYSTEIN | Council of Scientific and Industrial Research (IN) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015198341-A1 | METHOD FOR SELECTIVE DETECTION AND ESTIMATION OF HISTIDINE AND CYSTEIN | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155776-B2 | Method for selective detection and estimation of histidine and cystein | CTH, CISD2, SPR | PRCP 655/4885NOS2 469/4885NOS3 1137/4885 |
| US-20170240568-A1 | METHOD FOR SELECTIVE DETECTION AND ESTIMATION OF HISTIDINE AND CYSTEIN | CTH, CISD2, SPR | PRCP 655/4885NOS2 469/4885NOS3 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.